Guardant Health (GH) Research & Development (2017 - 2025)
Guardant Health (GH) has disclosed Research & Development for 9 consecutive years, with $98.3 million as the latest value for Q4 2025.
- Quarterly Research & Development rose 5.05% to $98.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $364.2 million through Dec 2025, up 4.73% year-over-year, with the annual reading at $364.2 million for FY2025, 4.73% up from the prior year.
- Research & Development hit $98.3 million in Q4 2025 for Guardant Health, up from $90.0 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $106.6 million in Q4 2022 to a low of $55.5 million in Q1 2021.
- Historically, Research & Development has averaged $85.8 million across 5 years, with a median of $88.0 million in 2025.
- Biggest five-year swings in Research & Development: skyrocketed 95.8% in 2021 and later dropped 15.69% in 2023.
- Year by year, Research & Development stood at $73.0 million in 2021, then soared by 45.96% to $106.6 million in 2022, then dropped by 15.69% to $89.9 million in 2023, then rose by 4.1% to $93.5 million in 2024, then increased by 5.05% to $98.3 million in 2025.
- Business Quant data shows Research & Development for GH at $98.3 million in Q4 2025, $90.0 million in Q3 2025, and $87.4 million in Q2 2025.